| Literature DB >> 28582235 |
Jonathan C Rawstorn1,2, Nicholas Gant2, Ian Warren3, Robert Neil Doughty4, Nigel Lever4, Katrina K Poppe4, Ralph Maddison1.
Abstract
BACKGROUND: Remote telemonitoring holds great potential to augment management of patients with coronary heart disease (CHD) and atrial fibrillation (AF) by enabling regular physiological monitoring during physical activity. Remote physiological monitoring may improve home and community exercise-based cardiac rehabilitation (exCR) programs and could improve assessment of the impact and management of pharmacological interventions for heart rate control in individuals with AF.Entities:
Keywords: cardiac rehabilitation; mHealth; rehabilitation; remote sensing technology; smartphone; telemedicine; telemetry
Year: 2015 PMID: 28582235 PMCID: PMC5454552 DOI: 10.2196/rehab.3633
Source DB: PubMed Journal: JMIR Rehabil Assist Technol ISSN: 2369-2529
Figure 1Zephyr BioHarness.
Figure 2Custom mobile app screenshot.
Participant characteristics (Phase One: participants in sinus rhythm; Phase Two: participants with atrial fibrillation).
|
| Phase One, mean (SD) | Phase Two, mean (SD) |
| Sample size/male | 10/6 | 8/5 |
| Age, years | 26.68 (3.26) | 69.68 (9.53) |
| Body mass, kg | 71.10 (11.53) | 77.46 (18.81) |
| Stature, m | 1.73 (0.06) | 1.69 (0.12) |
| Peak oxygen consumption, ml∙kg-1∙min-1 | 50.82 (4.51) | Not assessed |
Biases between BioHarness and reference heart rate (Phase One: participants in sinus rhythm; Phase Two participants with atrial fibrillation)a.
|
| Heart rate | ||||
| Median b∙min-1 | Bias b∙min-1 | Bias % | |||
| Phase One | Rest | REF | 72.00 (18.00) | 0.00 (4.45) | 0.02 (5.55) |
| BH | 70.75 (23.38) | ||||
| Transition | REF | 108.00 (30.00) | -0.80 (7.20) | -0.65 (7.38) | |
| BH | 97.00 (31.18) | ||||
| Run | REF | 162.00 (18.00) | -0.30 (4.60) | -0.20 (2.80) | |
| BH | 163.50 (16.40) | ||||
| Total | REF | 162.00 (24.00) | -0.30 (4.53)b | -0.20 (2.96) | |
| BH | 160.70 (13.40) | ||||
| Phase Two | Rest | REF | 84.00 (24.00) | 2.10 (4.55) | 2.06 (5.77) |
| BH | 89.10 (29.45) | ||||
| Transition | REF | 108.00 (6.00) | 1.10 (9.30) | 1.67 (8.78) | |
| BH | 91.70 (21.30) | ||||
| Walk | REF | 126.00 (40.50) | 0.65 (9.25) | 0.49 (7.82) | |
| BH | 130.20 (46.58) | ||||
| Cycle | REF | 120.00 (60.00) | 1.90 (11.50) | 1.79 (9.66) | |
| BH | 121.80 (72.50) | ||||
| Sweep | REF | 108.00 (27.00) | -3.60 (12.00) | -3.75 (9.70) | |
| BH | 103.10 (20.05) | ||||
| Vacuum | REF | 108.00 (30.00) | 3.20 (13.76) | 3.47 (13.46) | |
| BH | 101.30 (33.34) | ||||
| Total | REF | 108.00 (48.00) | 1.10 (9.75)c | 1.23 (8.61) | |
| BH | 106.55 (51.68) | ||||
aTable reports median (IQR) reference (REF) and BioHarness (BH) heart rates, absolute (b·min-1) and relative (%) biases.
b P=.003.
c P=.001.
Biases between BioHarness and reference respiratory rate (Phase One: participants in sinus rhythm; Phase Two participants with atrial fibrillation)a.
|
|
|
| Median br∙min-1 | Bias br∙min-1 b | Bias % |
| Phase One | Rest | REF | 17.00 (6.75) | -0.28 (4.00)tR | -1.56 (23.42) |
| BH | 16.15 (5.44) | ||||
| Transition | REF | 19.30 (7.33) | -2.20 (5.72)rR | -12.17 (29.52) | |
| BH | 17.65 (6.32) | ||||
| Run | REF | 41.70 (12.00) | -1.36 (4.58)rt | -3.30 (10.65) | |
| BH | 40.80 (10.09) | ||||
| Total | REF | 39.90 (15.30) | -1.25 (4.65)c | -3.33 (12.01) | |
| BH | 39.02 (13.40) | ||||
| Phase Two | Rest | REF | 18.50 (6.65) | -0.88 (4.30)twcsv | -4.89 (21.77) |
| BH | 17.29 (4.80) | ||||
| Transition | REF | 19.70 (8.30) | -5.73 (5.97)rwcsv | -28.02 (23.69) | |
| BH | 14.34 (4.92) | ||||
| Walk | REF | 22.30 (5.85) | 0.81 (6.34)rtsv | 3.12 (30.80) | |
| BH | 25.16 (6.35) | ||||
| Cycle | REF | 25.00 (7.28) | 0.28 (7.65)rtsv | 1.04 (28.84) | |
| BH | 26.69 (6.94) | ||||
| Sweep | REF | 22.00 (6.05) | 6.61 (16.35)rtwcv | 27.22 (77.73) | |
| BH | 31.03 (11.87) | ||||
| Vacuum | REF | 19.65 (9.33) | 9.42 (10.18)rtwcs | 43.89 (67.69) | |
| BH | 31.55 (9.72) | ||||
| Total | REF | 22.10 (7.18) | 0.39 (7.33)c | 1.56 (31.88) | |
| BH | 24.26 (11.02) |
aTable reports median (IQR) reference (REF) and BioHarness (BH) respiratory rates, absolute (br·min-1) and relative (%) biases.
bThe letters r t R= rest, transition, run; statistically significantly different compared to Phase One rest, transition, Run (P<.001 to P=.04). The letters r t w c s v = rest, transition, walk, cycle, sweep, vacuum; statistically significantly different compared to Phase Two rest, transition, walk, cycle, sweep, and vacuum (P<.001 to P=.02).
cStatistically significantly different compared to reference measures (P<.001).
Figure 3Sensor measurement error as a function of mean measurement magnitude (solid reference lines = mean biases, dashed reference lines = 95% limits of agreement).
Relative and absolute reliability of BioHarness heart rate and respiratory rate measuresa.
|
| Relative | Absolute | ||||
|
| rho | ICC | SEM, min-1 | LoA, min-1 | CV, % | |
| Phase One | HR | .92b | .98b | 5.20 | (-21.87, 9.26) | 2.24 |
| RR | .87b | .94b | 2.78 | (-13.73, 9.41) | 7.94 | |
| Phase Two | HR | .97b | .98b | 4.77 | (-13.39, 23.79) | 4.05 |
| RR | .43b | .55b | 4.60 | (-11.58, 18.91) | 16.61 | |
aTable reports Spearman’s rank-order correlation coefficient (rho), two-way random effects intraclass correlation coefficient (ICC), standard error of measurement (SEM), non-parametric 95% limits of agreement (LoA), and coefficient of variation (CV) for heart rate (HR) and respiratory rate (RR).
bStatistically significant P<.001.